Statins and breast cancer prognosis: evidence and opportunities

T. P. Ahern, T. L. Lash, P. Damkier, P. M. Christiansen, D. P. Cronin-Fenton

Research output: Contribution to journalComment/debateResearchpeer-review


Much preclinical and epidemiological evidence supports the anticancer effects of statins. Epidemiological evidence does not suggest an association between statin use and reduced incidence of breast cancer, but does support a protective effect of statins-especially simvastatin-on breast cancer recurrence. Here, we argue that the existing evidence base is sufficient to justify a clinical trial of breast cancer adjuvant therapy with statins and we advocate for such a trial to be initiated without delay. If a protective effect of statins on breast cancer recurrence is supported by trial evidence, then the indications for a safe, well tolerated, and inexpensive treatment can be expanded to improve outcomes for breast cancer survivors. We discuss several trial design opportunities-including candidate predictive biomarkers of statin safety and efficacy-and off er solutions to the key challenges involved in the enrolment, follow-up, and analysis of such a trial.
Original languageEnglish
JournalLancet Oncology
Issue number10
Pages (from-to)E461-E468
Publication statusPublished - Sept 2014

Cite this